Diyetressa

General characteristics. Structure:

Active agents: Antibodies to a kannabinoidny receptor of 1 type affinely cleared - 0,006 g *
Excipients: lactoses monohydrate, cellulose microcrystallic, magnesium stearate.

* are applied on lactose in the form of mix of three active aqueous-alcoholic cultivations of the substance divorced respectively in ^{10012, 10030}, ¹⁰⁰²⁰⁰ times.

Description
tablets of a ploskotsilindrichesky form, with risky and a facet, from white till almost white color. On the flat party from risky MATERIA MEDICA text is put, on other flat party DIETRESSA text is put.

Pharmacological properties:

Pharmacodynamics: via mechanisms of allosteric modulation drug sensitizirut a kannabinoidny receptor of the I type that is followed by increase in its sensitivity to endogenous kannabinoidny neuropeptids. Thereof endokannabinoidny regulation of mesolimbic system, including the food center in a hypothalamus is normalized. It is experimentally shown that at administration of drug the refusal of self-stimulation of a lateral hypothalamus testimonial of saturation of system of a positive emotional reinforcement, reduction of the eyforigenny importance of food happens an animal. Administration of drug is followed by reduction of consumption of food and weight reduction, without causing the influence on higher nervous activity both braking, and stimulating. The effect of weight reduction is caused not only the central, but also peripheral mechanisms – due to modulation of kannabinoidny receptors of adipocytes (lipoblasts), activation in them standard metabolism. Drug does not cause accustoming, medicinal dependence, has no narcogene effect.

Pharmacokinetics: sensitivity of modern physical and chemical methods of the analysis (gas-liquid chromatography, highly effective liquid chromatography, chromaTO - mass spectrometry) does not allow to estimate the maintenance of midget doses of antibodies in biological liquids, bodies and fabrics that makes technically impossible studying of pharmacokinetics of drug.

Indications to use:

Long therapy of patients with the excess body weight or obesity of the I-II degree (an index of body weight  of 25 kg/sq.m) in combination with moderately hypocaloric diet.

Route of administration and doses:

Inside. On one reception - 1 tablet (to hold in a mouth before full dissolution). To apply on 1 tablet from two to four times a day in 15-30 minutes prior to food. It is desirable to combine treatment with moderately hypocaloric diet. To accept it is long – up to three months. If necessary the course can be renewed

Features of use:

 Lactose in this connection patients are not recommended to appoint it with an inborn galactosemia, a sprue of glucose or a galactose, or at an inborn lactose intolerance is a part of drug. Diyetressa does not exert impact on ability of control of vehicles and other potentially dangerous mechanisms. In a small amount of cases at the beginning of a course of therapy by Diyetressa the slight increase of appetite which is not causing increase in weight and not demanding drug withdrawal can be observed temporary (from two to eight days).

Side effects:

When using drug according to the specified indications and in the specified dosages of side effect it is not revealed. Reactions of the increased individual sensitivity to drug components are possible.

Interaction with other medicines:

Cases of incompatibility with other medicines are not registered so far.

Contraindications:

The increased individual sensitivity to drug components. Diyetressa is not recommended for use for children aged up to 18 years in connection with insufficiency of data on efficiency and safety for this age.

Use at pregnancy and during breastfeeding
safety of use of Diyetressa for pregnant women and in the period of a lactation was not studied. In need of administration of drug it is necessary to consider a ratio risk/advantage.

Overdose:

Overdose cases are not registered so far. At accidental overdose the dispepsichesky phenomena caused by the fillers which are a part of drug are possible.

Storage conditions:

Tablets for a rassasyvaniye. On 20 tablets in a blister strip packaging from a film of polyvinyl chloride or aluminum foil. On 1, 2 or 5 blister strip packagings together with the instruction on a medical use place in a pack from a cardboard.

Issue conditions:

Without recipe

Packaging:

In the place protected from light, at a temperature not above 25 °C. To store in the place, unavailable to children. A period of storage - 3 years. Not to apply after a period of validity.